Juno Pharmaceuticals' sales of relma-cel reached 174 million yuan in 2023

On March 20th, Juno Pharmaceuticals released its full-year performance for 2023, with revenue totaling 173.9 million yuan, a 19.3% increase compared to last year's 145.7 million yuan. Juno Pharmaceuticals currently has only one commercialized product, CD19 CAR-T therapy relma-cel, meaning that the sales of relma-cel in 2023 amounted to 173.9 million yuan. In 2023, Juno Pharmaceuticals issued 184 prescriptions for relma-cel and completed 168 infusions. Sales expenses amounted to 113.2 million yuan, a 40.7% decrease year-on-year. This decrease is mainly attributed to Juno Pharmaceuticals optimizing its commercial personnel structure to support the commercialization of relma-cel more efficiently, resulting in reduced employee welfare expenses. Additionally, the decrease is due to reduced business promotion and professional service fees. Research and development expenses increased by 1.4% year-on-year to 413.6 million yuan. As of December 31, 2023, cash and cash equivalents amounted to 1.0059 billion yuan."